TY  - JOUR
ID  - discovery1454494
N2  - Ischaemic heart disease (IHD) remains the leading cause of death and disability worldwide. As a result, novel therapies are still needed to protect the heart from the detrimental effects of acute ischaemia-reperfusion injury, in order to improve clinical outcomes in IHD patients. In this regard, although a large number of novel cardioprotective therapies discovered in the research laboratory have been investigated in the clinical setting, only a few of these have been demonstrated to improve clinical outcomes. One potential reason for this lack of success may have been the failure to thoroughly assess the cardioprotective efficacy of these novel therapies in suitably designed preclinical experimental animal models. Therefore, the aim of this Position Paper by the European Society of Cardiology Working Group Cellular Biology of the Heart is to provide recommendations for improving the preclinical assessment of novel cardioprotective therapies discovered in the research laboratory, with the aim of increasing the likelihood of success in translating these new treatments into improved clinical outcomes.
KW  - Animal models
KW  -  Cardioprotection
KW  -  Ischaemia
KW  -  Myocardial infarction
KW  -  Reperfusion
EP  - 411
AV  - public
Y1  - 2014/10/24/
TI  - ESC Working Group Cellular Biology of the Heart: Position Paper: improving the preclinical assessment of novel cardioprotective therapies
SN  - 0008-6363
UR  - http://dx.doi.org/10.1093/cvr/cvu225
A1  - Lecour, S
A1  - Bøtker, HE
A1  - Condorelli, G
A1  - Davidson, SM
A1  - Garcia-Dorado, D
A1  - Engel, FB
A1  - Ferdinandy, P
A1  - Heusch, G
A1  - Madonna, R
A1  - Ovize, M
A1  - Ruiz-Meana, M
A1  - Schulz, R
A1  - Sluijter, JP
A1  - Van Laake, LW
A1  - Yellon, DM
A1  - Hausenloy, DJ
JF  - Cardiovasc Res
SP  - 399
VL  - 104
N1  - © The Author 2014. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-
Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com 
IS  - 3
ER  -